The Indian pharmaceutical sector is expanding rapidly, owing to the remarkable success of its main corporations. The Top 20 pharmaceutical Companies India play a critical role in defining global healthcare trends, supporting innovation, and increasing India's status as a powerhouse in both specialty and generic pharmaceuticals. Established heavyweights like as Sun Pharmaceutical, Dr. Reddy's Laboratories, Cipla, Divi's Laboratories, and Lupin have helped India emerge as a worldwide pharmaceutical powerhouse. Along with them, rising innovators such as Steris Healthcare Pvt Ltd are making amazing breakthroughs in quality, affordability, and scale.

Top 20 Pharmaceutical Companies in India (FY25)

Sun Pharmaceutical Industries Ltd

Revenue: ₹52,041 crore (9% YoY growth)

Highlight: India’s top pharma company with 8% domestic market share and US$1.92 billion in U.S. sales.

About: Sun Pharmaceutical Industries is one of India's major pharmaceutical companies by total sales. It is the fourth largest specialized generic pharmaceutical firm in the world. It also sells Carbamazepine, Etodolac, Clorazepate, anti-cancer medications, steroids, peptides, sex hormones, and banned drugs. Its subsidiaries include Ranbaxy Laboratories, Sun Petrochemical Pvt. Ltd, Sun Ophthalmic Inc, Alkaloida Chemical Company Zrt, and Chattem Chemicals Inc. This drugstore sells inexpensive medications in over 150 nations across six continents.
 

Dr. Reddy’s Laboratories Ltd

Revenue: ₹31,229 crore

Highlight: 47% of revenue from the U.S.; broad pipeline and solid profitability.

About: Anji Reddy created Dr. Reddy’s Laboratories in 1984. It is an Indian multinational pharmaceutical corporation. It is well-known in India and throughout the world for producing a diverse variety of medicinal products. They provide more than 190 drugs, 60 active pharmaceutical components for drug producers, diagnostic kits, critical care, and biotechnology items. Its revenue in 2023 was INR 25,725.20 crore. Dr. Reddy's significant products include canagliflozin. Ramipril, ibuprofen, naproxen, atorvastatin, nizatidine, naproxen sodium, etc.

Aurobindo Pharma

Revenue: ₹30,922 crore

Highlight: Global leader in generics and APIs; presence in 150+ countries.

About: Aurobindo Pharma Limited was formed in 1986. It offers approximately 300 items in 125 countries, and APIS is its major division, accounting for 35% of total sales. It is the second-largest pharmaceutical firm in India, with a sales of INR 25,145.97 crore in 2023. Aurobindo Pharma Limited manufactures and sells medications in the disciplines of neurology, cardiovascular, antiretrovirals, anti-diabetics, gastrointestinal, cephalosporins, and so on.
 

Steris Healthcare Pvt Ltd

Revenue: ₹110.68 crore+

Headquarters: Navi Mumbai

Highlight: Rapidly growing company known for high-quality specialty formulations. Recently surpassed ₹100 crore in annual revenue; plans for IPO and 800+ new job opportunities across South India. 

About: We are delighted to introduce ourselves as STERIS HEALTHCARE PVT LTD, a specialty pharmaceutical company formed in the May month of year 2018 by a group of extensively proficient pharmaceutical professionals. Steris is offering an extensive variety of Pharmaceutical products in all niche super specialty segment to the Healthcare industry at the most affordable cost. From quality and niche products STERIS HEALTHCARE PVT LTD grow rapidly in all segments. STERIS HEALTHCARE products range covers almost every cadre of requirement in today's Medical scenario, widely prescribed under categories like Cardiology, Asthama, Respiratory, Nasal, Diabetic, Endocrinology, Cardiology, Gastrology, Orthopaedic, Anti-infective/antibiotic, General, Urology, Neurology, Nephrology, Oncology, Gynaecology, Pediatric, Dental & Derma range of Products.

Cipla Ltd

Revenue: ₹26,982 crore

Highlight: Market leader in respiratory and HIV therapies; nearly 50% revenue from exports.

About: Cipla is an Indian multinational pharmaceutical and biotechnology corporation headquartered in Mumbai and founded in 1935 by Khwaja Abdul Hamied. Yusuf Hamied is Cipla's non-executive chairman. This Indian pharmaceutical business specializes in the development of drugs for respiratory and cardiovascular illnesses, arthritis, diabetes, weight management, depression, and other conditions.
 

Zydus Lifesciences

Revenue: ₹22,247 crore

Highlight: 45% of revenue from the U.S.; strong presence in chronic and respiratory care.

About: Zydus Lifesciences Limited (previously Cadila Healthcare) was founded in 1952 by Ramabhai Patel. It is sometimes referred to as Zydus Cadila. It is an Indian pharmaceutical firm based in Ahmedabad. It is one of India's top pharmaceutical firms, with revenues of INR 17,424 crore in 2023. Zydus Lifesciences Limited is also noted for providing superior diagnostics, as well as producing herbal, cosmetics, and other over-the-counter items. The business also develops generics for hepatitis C therapy under a voluntary licensing arrangement with Gilead. Cadila manufactures API in three locations in India: the Ankleshwar factory, the Vadodara facility, and Patalganga.

Lupin Ltd

Revenue: ₹22,002 crore

Highlight: Stronghold in metabolic and respiratory segments; 37% of sales from the U.S. 

About:  Lupin is a significant Indian multinational pharmaceutical business headquartered in Mumbai that develops, manufactures, and markets generic and branded pharmaceuticals. Desh Bandhu Gupta established Lupin in 1968. It is the 12th-largest firm in terms of market value, making it one among India's most well-known pharmaceutical makers. Lupin's sales was INR 16,715.02 crore in 2023. The firm manufactures and sells pharmaceuticals in a variety of categories, including pediatrics, cardiovascular, anti-infectives, diabetology, asthma, and TB.
 

Biocon Ltd

Revenue: ₹14,762 crore

Highlight: Global leader in biosimilars; 44% of total revenue from the U.S. 

About: Biocon was founded in 1978 and is India's most popular pharmaceutical firm. Biocon Limited produces generic active medicines. The firm is situated in Bengaluru. Biocon Limited's products are widely sold over the world. More than 9000 people are employed at Biocon and the company holds total assets valued at over $824 million.
 

Glenmark Pharmaceuticals

Revenue: ₹13,128 crore

Highlight: Innovator in biosimilars and specialty generics; operations in 80+ countries. 

About: Glenmark Pharma Limited is a pharmaceutical firm based in Mumbai, India, founded in 1977 by Gracias Saldanha. This pharmaceutical business specializes on drug discovery, which is significant in the fields of dermatology, respiratory medicine, and cancer. It is the ninth largest pharmaceutical firm, with a revenue of INR 13,306.90 crores in 2023. Collaboration with big pharmaceutical firms allowed the company to focus on novel biosimilar treatments as well as cancer, dermatological, and respiratory illnesses.
 

Alkem Laboratories

Revenue: ₹12,757 crore

Highlight: Wide domestic footprint with diverse prescription and OTC portfolio.

About:  Alkem, also known as Alkem Laboratories Ltd., is a Mumbai-based Indian multinational pharmaceutical company that manufactures and sells pharmaceutical generics, formulations, and nutraceuticals in India and around the world. Its revenue in 2023 was INR 11,815.34 crore. As of September 2021, Alkem Laboratories has successfully established 21 production units, including 19 in India and two in the United States. Alkem has been popular for almost five decades. In 2006, Taxim from Alkem became the first anti-infective medicine to reach a domestic sales total of $1,000 million. 

Torrent Pharmaceuticals

Revenue: ₹11,302 crore

Highlight: Specialization in CNS and cardiovascular therapies; consistent CAGR.

About:  Torrent Pharmaceuticals is a significant Indian multinational pharmaceutical firm that produces generic medications and active pharmaceutical components. It is headquartered in Ahmedabad and has a revenue of INR 9,665.29 crore as of 2023. Torrent has manufacturing units in Dahej, Pithampur, Gujarat, and Madhya Pradesh. Torrent Pharma manufactures medications for the Central Nervous System, gastrointestinal pain management, gastrointestinal diabetes, and anti-infective sectors. It is dedicated to offering high-quality and economical healthcare solutions to patients all around the world.
 

Mankind Pharma

Revenue: ₹9,326 crore

Highlight: Dominates OTC and gynecology markets; rapidly growing prescription segment.

About:  Mankind Pharma Limited is a pharmaceutical firm in India with its headquarters in New Delhi. It was formed in 1995 and manufactures and sells a variety of medications, including antibiotics, antifungals, NSAIDs, gastrointestinal, anthelmintic, cardiovascular, dermal, erectile dysfunction, and others. In 2023, the firm generated roughly INR 8,878 crore in revenue, making it one of the top Indian pharmaceutical companies.
 

Divi’s Laboratories

Revenue: ₹9,078 crore

Highlight: Among the top global API exporters; Q4 net profit ₹667 crore. 

About: Divi's Laboratories Limited ranks among India's top 20 pharmaceutical companies. This Indian multinational pharmaceutical business, based in Hyderabad, has had a considerable impact on the worldwide pharmaceutical sector. Divi’s Laboratories was formed in 1990. Divi Laboratories Ltd. produces active pharmaceutical ingredients (APIs) and intermediates. This pharmaceutical company in India manufactures top generic compounds, nutraceutical components, custom API synthesis, and intermediates for worldwide innovator companies. Divi's Laboratories is one of the world's largest API firms, with an estimated turnover of INR 8,112.17 crore in 2023 and exports to over 95 countries.
 

Piramal Enterprises

Revenue: ₹8,949 crore

Highlight: Operates in diagnostics, healthcare, and contract manufacturing. 

About: Piramal Enterprises Limited is one of India's most popular pharmaceutical firms. It was established in 1984 and purchased by Ajay Piramal in the early 1980s. The multinational corporate giant works in healthcare, life sciences, medication research, and other areas. The corporation also works with pharmaceuticals, critical care, consumer items, phytomedicine, and imaging. Piramal Enterprises Limited expects a total revenue of INR 9,086.74 crore in 2023.
 

IPCA Laboratories

Revenue: ₹8,726 crore

Highlight: Major exporter of formulations and APIs; focus on anti-inflammatory and anti-malarial drugs.

Abbott India

Highlight: A major multinational subsidiary with strong Indian presence in pharmaceuticals, diagnostics, and nutrition.

Alembic Pharmaceuticals

Highlight: Specializes in anti-retroviral and oncology drugs; modern manufacturing base in Gujarat.

Emcure Pharmaceuticals

Highlight: Growing presence in generics and biosimilars across India, Europe, and the U.S.

Natco Pharma

Highlight: Well-known for oncology and complex generics; respected for affordable cancer therapies.

Laurus Labs

Highlight: Leading supplier of APIs globally; expanding in biotech, CDMO, and nutraceuticals.

Why Steris Healthcare Pvt Ltd Is Among the Best Pharmaceutical Brands in India

As the Indian pharmaceutical landscape continues to expand globally, Steris Healthcare Pvt Ltd stands out for its dedication to quality, innovation, and affordability. While legacy brands lead the market, Steris Healthcare is setting new benchmarks as an emerging name driven by a patient-centric approach and WHO-GMP-certified manufacturing excellence.

India’s pharmaceutical industry is growing rapidly on a global scale, with the top 20 pharma companies playing a pivotal role in this advancement. From long-established giants like Sun Pharma to emerging innovators such as Steris Healthcare Pvt. Ltd., these companies are setting new benchmarks in accessibility, innovation, and pharmaceutical manufacturing excellence.

Steris Healthcare has swiftly risen to prominence as one of India’s most trusted and respected pharmaceutical firms. Known for its unwavering commitment to quality, patient-centric innovation, and cost-effective healthcare, the company continues to deliver WHO-GMP-certified medicines that meet both national and international standards. Its dedication to affordability and therapeutic value sets it apart in the competitive Indian pharmaceutical landscape.

Offering a wide spectrum of healthcare solutions, Steris Healthcare’s product range spans various therapeutic segments, including cardiology, diabetology, gastroenterology, urology, neurology, gynecology, and more. With a strong foundation built on experienced professionals, state-of-the-art manufacturing units, and rigorous quality assurance protocols, the company ensures every product delivers purity, safety, and efficacy. Steris Healthcare’s growing reputation among healthcare providers, distributors, and patients reflects its mission to bridge the gap between cutting-edge science and everyday healthcare needs across India.